SAN DIEGO (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized the repurchase of up to $500 million of the firm's common stock during fiscal year 2013.

The company said that the new repurchase program replaces an existing stock repurchase program that had authorized the repurchase of shares to eliminate or reduce share dilution from equity programs.

Agilent finished its 2012 fiscal year on Oct. 31, 2012. It held $2.35 billion in cash and cash equivalents as of that date.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.